Carcinogenesis, Teratogenesis & Mutagenesis ›› 2019, Vol. 31 ›› Issue (3): 216-221.doi: 10.3969/j.issn.1004-616x.2019.03.008

Previous Articles     Next Articles

Expression of miR-200b-3p and PAK2 in chemotherapy-resistant and sensitive ovarian cancers

WAN Shuquan1, WEI Lijun2, WANG Fuhua3, ZENG Yong2   

  1. 1. Second Clinical Medical College of Shanxi Medical University, Taiyuan 030001;
    2. Department of Gynecology, Affiliated Tumor Hospital of Shanxi Medical University, Taiyuan 030013;
    3. Department of Molecular Biology, Affiliated Tumor Hospital of Shanxi Medical University, Taiyuan 030013, Shanxi, China
  • Received:2018-12-03 Revised:2019-04-23 Online:2019-05-31 Published:2019-05-31

Abstract: OBJECTIVE: To investigate the expression and clinical significance of miR-200b-3p and PAK2 mRNA in chemotherapy-resistant and sensitive ovarian cancers. METHODS: Bioinformatics method combined with comprehensive literature analyses were used to predict the target gene of miR-200b-3p as PAK2. From 2015 to 2018,25 tissue samples from patients with chemo-resistant ovarian cancers and 25 from chemo-sensitive ovarian cancers were collected from Shanxi Provincial Cancer Hospital. Relative expression of miR-200b-3p and PAK2 mRNA from the two groups of tissues were detected by using quantitative real-time PCR (qPCR). Their expression levels and clinic-pathological parameters of the two groups of cancer patients were compared. RESULTS:The expression level of miR-200b-3p was 15.78 times and significantly higher in the chemo-resistant ovarian cancer tissues than the sensitive ones. However, the expression level of PAK2 mRNA was 0.03 times and significantly lower in the resistant and in the sensitive tissues. The expression levels of miR-200b-3p and PAK2 mRNA were significantly correlated with the clinical stage and lymph node metastasis of ovarian cancer patients (P<0.05). CONCLUSION:Our data show that over-expression of miR-200b-3p and regulation of PAK2 mRNA were involved in the expression of chemoresistance and the promotion of ovarian cancer metastasis.

Key words: ovarian cancer, chemotherapy resistance, miR-200b-3p, PAK2 mRNA

CLC Number: